AdaptHealth Corp. Form 8-K Summary
Business Context and Reporting Period
Date of Report: May 25, 2020
Company: AdaptHealth Corp. (AHCO)
Event: Entry into a Material Definitive Agreement to acquire Solara Holdings, LLC ("Solara") and LCP Solara Blocker Corp. ("Blocker").
AdaptHealth Corp. announced the execution of a Stock Purchase Agreement and Agreement and Plan of Merger to acquire Solara, a provider of home medical equipment and services. The transaction is expected to close in June or July 2020, subject to customary closing conditions and regulatory approvals.
Key Financial Metrics and Transaction Terms
Acquisition Consideration:
- Total Base Purchase Price: $425,000,000
- Structure: Combination of cash and 3,906,250 shares of AdaptHealth Class A Common Stock (valued at $16.00 per share).
- Escrow: Approximately $10 million withheld to fund potential indemnification matters.
- Adjustments: Cash portion subject to adjustments for cash, indebtedness, transaction expenses, and net working capital.
Financing Arrangements:
- Equity Financing (OEP Investment): Agreement to raise up to $190,000,000 via private placement of Class A Common Stock and Series A Convertible Preferred Stock from One Equity Partners (OEP).
- Debt Financing: Commitment letter for an incremental secured term loan facility of up to $240,600,000 from a syndicate including Regions Bank, Citizens Bank, Deutsche Bank, and Royal Bank of Canada.
- Other Equity: Letter agreement with Deerfield Partners for an exchange of existing holdings and a potential $35,000,000 investment in Series B-2 Preferred Stock.
Financial Performance: The filing text does not provide specific revenue, profit, cash flow, or margin figures for AdaptHealth or Solara for the current or prior periods.
Material Changes and Agreements
The filing details several material agreements executed on May 25, 2020:
- Put/Call Option Agreement: AdaptHealth granted certain existing shareholders (BlueMountain funds) the right to sell up to 1,898,967 shares/units to the Company between closing and October 31, 2020, at a price of the greater of $14.50 or 85% of the 30-day VWAP. Conversely, the Company has the right to call these shares at $15.76 per share.
- Board Composition: AdaptHealth agreed to increase its board size by two members, with OEP designating one director and the Company nominating one independent director.
- Debt Restructuring: AdaptHealth agreed to pay all PIK interest on existing BlueMountain notes in cash following the acquisition closing, rather than accruing it to principal.
Guidance, Risks, and Contingencies
Outlook and Conditions:
- Closing Timeline: Expected in June or July 2020.
- Regulatory: Subject to Hart-Scott-Rodino (HSR) waiting period expiration and absence of legal orders barring the acquisition.
- Stockholder Approval: Required for the conversion of Series A Preferred Stock and Series B-2 Preferred Stock into common stock to comply with Nasdaq Listing Rule 5635. Voting agreements have been secured representing over 50% of current voting power to support this approval.
Risks and Contingencies:
- Termination Rights: Either party may terminate if the acquisition is not consummated within 120 days (extendable by 30 days by Solara/Blocker Seller).
- Material Adverse Effect (MAE): Representations and warranties are qualified by an MAE standard.
- Forward-Looking Risks: The filing cites risks related to the COVID-19 pandemic, changes in healthcare sector competition, client preferences, and potential governmental investigations or litigation.
Investor Verification Checklist
- Financing Confirmation: Verify the final execution of the $240.6 million debt facility and the $190 million OEP equity investment, as definitive documentation was not finalized at the time of filing.
- Stockholder Approval: Monitor the upcoming stockholder meeting to confirm approval for the removal of conversion restrictions on preferred stock.
- Working Capital Adjustments: Review the final purchase price adjustments based on Solara's net working capital at closing.
- Regulatory Clearance: Confirm the expiration of the HSR waiting period and absence of antitrust challenges.
- Deerfield Terms: Verify the final terms of the Exchange Agreement and Series B-2 Preferred Stock purchase, as these were subject to further negotiation.